Antimicrobial, Antitumor and Side Effects Assessment of a Newly Synthesized Tamoxifen Analog

Author(s): Fatma Abdmouleh, Mehdi El Arbi*, Hajer Ben Saad, Karim Jellali, Emna Ketata, Ibtissem Ben Amara, Pascal Pigeon, Hanen Ben Hassen, Siden Top, Gérard Jaouen, Riadh Hammami*, Mamdouh Ben Ali, Girish Kumar Gupta

Journal Name: Current Topics in Medicinal Chemistry

Volume 20 , Issue 25 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Tamoxifen citrate is a very prevalent drug marketed under several trade names like Apo-Tamox, Nolvadex, Tamec, Tamizam, and Tamoplex. This molecule is approved by the FDA for breast cancer treatment. Some studies have shown that tamoxifen has anti-tuberculosis and antiparasitic activities. Like any drug, tamoxifen possesses side effects, more or less dangerous.

Aims: Basically, this work is a comparative study that aims to: primarily compare the antimicrobial and antitumor activities of tamoxifen and a newly synthesized tamoxifen analog; and to determine the molecule with lesser side effects.

Methods: Three groups of mice were injected with tamoxifen citrate and compound 2(1,1-bis[4-(3- dimethylaminopropoxy)phenyl]-2-phenyl-but-1-ene dihydrochloride) at doses corresponding to C1 (1/10), C2 (1/50), and C3 (1/100) to compound 2 lethal dose (LD50 = 75 mg/kg) administered to adult mice. A group of noninjected mice served as a study control.

Results: Experimental results suggest that compound 2 has better antitumor and antimicrobial activity than tamoxifen citrate besides its lower toxicity effects.

Conclusion: The results obtained from the present study confirmed the antitumor and antimicrobial effect of tamoxifen citrate and its hematological side effects. Compound 2 seems to be more effective than tamoxifen citrate for antitumor and antimicrobial treatment while having less hematological side effects and less disruption of the blood biochemical parameters. These findings encourage us to perform further studies on compound 2 and test it for other therapeutic uses for which tamoxifen was found effective.

Keywords: Tamoxifen citrate, 1;1-bis[4-(3-dimethylaminopropoxy)phenyl]-2-phenyl-but-1-ene dihydrochloride, Antimicrobial activity, Antitumor, Toxicity, Mice.

[1]
Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no eskape! an update from the infectious diseases society of America. Clin. Infect. Dis., 2009, 48(1), 1-12.
[http://dx.doi.org/10.1086/595011 ] [PMID: 19035777]
[2]
Fair, R.J.; Tor, Y. Antibiotics and bacterial resistance in the 21st century. Perspect. Medicin. Chem., 2014, 6, 25-64.
[http://dx.doi.org/10.4137/PMC.S14459 ] [PMID: 25232278]
[3]
von Brunn, A. Editorial overview: Engineering for viral resistance. Curr. Opin. Virol., 2015, 14, v-vii.
[http://dx.doi.org/10.1016/j.coviro.2015.08.009 ] [PMID: 26320757]
[4]
El-Tanani, M.; Dakir, H.; Raynor, B.; Morgan, R. Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers (Basel), 2016, 8(3), 35.
[http://dx.doi.org/10.3390/cancers8030035 ] [PMID: 26985906]
[5]
Liu, Y.; Li, Q.; Zhou, L.; Xie, N.; Nice, E.C.; Zhang, H.; Huang, C.; Lei, Y. Cancer drug resistance: redox resetting renders a way. Oncotarget, 2016, 7(27), 42740-42761.
[http://dx.doi.org/10.18632/oncotarget.8600 ] [PMID: 27057637]
[6]
WHO. Antimicrobial resistance: global report on surveillance; World Health Organization: Geneva, 2014.
[7]
Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov., 2013, 12(5), 371-387.
[http://dx.doi.org/10.1038/nrd3975 ] [PMID: 23629505]
[8]
Infectious Diseases Society of America. The 10 x ’20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis., 2010, 50(8), 1081-1083.
[http://dx.doi.org/10.1086/652237 ] [PMID: 20214473]
[9]
Maximov, P.Y.; McDaniel, R.E.; Jordan, V.C. Carcinogenesis and tamoxifen. In: Tamoxifen Pioneering Medicine in Breast Cancer; Springer: Basel, 2013, pp. 101-114.
[10]
Jordan, V.C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov., 2003, 2(3), 205-213.
[http://dx.doi.org/10.1038/nrd1031 ] [PMID: 12612646]
[11]
Cohen, M.H.; Hirschfeld, S.; Flamm Honig, S.; Ibrahim, A.; Johnson, J.R.; O’Leary, J.J.; White, R.M.; Williams, G.A.; Pazdur, R. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist, 2001, 6(1), 4-11.
[http://dx.doi.org/10.1634/theoncologist.6-1-4 ] [PMID: 11161223]
[12]
FDA. Nolvadex . (tamoxifen citrate) prescribing information; Zeneca Pharmaceuticals: Cambridge, 1998.
[13]
Purvis, J. Dear doctor letter regarding warning information on serious or fatal adverse effects among women receiving tamoxifen for risk reduction; AstraZeneca Pharmaceuticals: Wilmington, DE, 2002.
[14]
Osborne, C.K.; Osborne, C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med., 1998, 339(22), 1609-1618.
[http://dx.doi.org/10.1056/NEJM199811263392207 ] [PMID: 9828250]
[15]
Fisher, B.; Costantino, J.P.; Wickerham, D.L.; Cecchini, R.S.; Cronin, W.M.; Robidoux, A.; Bevers, T.B.; Kavanah, M.T.; Atkins, J.N.; Margolese, R.G.; Runowicz, C.D.; James, J.M.; Ford, L.G.; Wolmark, N. Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project p-1 study. J. Natl. Cancer Inst., 2005, 97(22), 1652-1662.
[http://dx.doi.org/10.1093/jnci/dji372 ] [PMID: 16288118]
[16]
Jang, W.S.; Kim, S.; Podder, B.; Jyoti, M.A.; Nam, K-W.; Lee, B-E.; Song, H-Y. Anti-mycobacterial activity of tamoxifen against drug-resistant and intra-macrophage mycobacterium tuberculosis. J. Microbiol. Biotechnol., 2015, 25(6), 946-950.
[http://dx.doi.org/10.4014/jmb.1412.12023 ] [PMID: 25639719]
[17]
Trinconi, C.T.; Reimão, J.Q.; Coelho, A.C.; Uliana, S.R.B. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. J. Antimicrob. Chemother., 2016, 71(5), 1314-1322.
[http://dx.doi.org/10.1093/jac/dkv495 ] [PMID: 26851606]
[18]
El Arbi, M.; Pigeon, P.; Rkhis, A.C.; Top, S.; Rhouma, A.; Rebai, A.; Jaouen, G.; Aifa, S. Antimicrobial effect of ferrocenyl diaryl butenes against olive plantlet diseases. J. Plant Pathol., 2011, 93(3), 651-657.
[19]
El Arbi, M.; Pigeon, P.; Top, S.; Rhouma, A.; Aifa, S.; Rebai, A.; Vessières, A.; Plamont, M-A.; Jaouen, G. Evaluation of bactericidal and fungicidal activity of ferrocenyl or phenyl derivatives in the diphenyl butene series. J. Organomet. Chem., 2011, 696(5), 1038-1048.
[http://dx.doi.org/10.1016/j.jorganchem.2010.09.015]
[20]
El Arbi, M.; Théolier, J.; Pigeon, P.; Jellali, K.; Trigui, F.; Top, S.; Aifa, S.; Fliss, I.; Jaouen, G.; Hammami, R. Antibacterial properties and mode of action of new triaryl butene citrate compounds. Eur. J. Med. Chem., 2014, 76, 408-413.
[http://dx.doi.org/10.1016/j.ejmech.2014.02.037 ] [PMID: 24602786]
[21]
El Arbi, M.; Jalléli, K.; Trigui, F.; Pigeon, P.; Görmen, M.; Top, S.; Aifa, S.; Fliss, I.; Jaouen, G.; Hammami, R. Efficacy of a novel ferrocenyl diaryl butene citrate compound as a biocide for preventing healthcare associated infections. Med. Chem. Comm, 2016, 7(5), 948-954.
[http://dx.doi.org/10.1039/C5MD00568J]
[22]
Arbi, M.E.; Ketata, E.; Neifar, A.; Mihoubi, W.; Gupta, G.K.; Pigeon, P.; Top, S.; Gargouri, A.; Jaouen, G. Aryl butenes active against K562 cells and lacking tyrosinase inhibitory activity as new leads in the treatment of leukemia. Mini Rev. Med. Chem., 2018, 18(15), 1294-1301.
[http://dx.doi.org/10.2174/1389557517666170208142254 ] [PMID: 28183263]
[23]
Jellali, K.; Pigeon, P.; Trigui, F.; Top, S.; Aifa, S.; Jaouen, G.; El Arbi, M. Effect of the amino chain length and the transformation into citric acid salts of aryldiphenyl-butenes and ferrocenyldiphenylbutenes bearing two dimethylaminoalkyl chains on their antimicrobial activities SpringerPlus, 2 , 2013, 508, 1-9.
[24]
Ketata, E.; Neifar, A.; Mihoubi, W.; Pigeon, P.; Gouzi, H.; Mallet, J-M.; Top, S.; Gupta, G.K.; Jaouen, G.; Gargouri, A.; El Arbi, M. The inhibition of tyrosinase by some aryl butenes: A desired activity or a side effect to avoid. J. Organomet. Chem., 2017, 848, 133-141.
[http://dx.doi.org/10.1016/j.jorganchem.2017.07.031]
[25]
Pigeon, P.; Top, S.; Vessières, A.; Huché, M.; Gormen, M.; El Arbi, M.; Plamont, M-A.; McGlinchey, M.J.; Jaouen, G. A new series of ferrocifen derivatives, bearing two aminoalkyl chains, with strong antiproliferative effects on breast cancer cells. New J. Chem., 2011, 35(10), 2212-2218.
[http://dx.doi.org/10.1039/c1nj20192a]
[26]
Maryland, R.C. Guide for the care and use of laboratory animals. Institute of Laboratory Animal Resources Commission on Life Sciences; National Research Council National Academy Press: Washington, DC, 1996.
[27]
Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18(6), 499-502.
[http://dx.doi.org/10.1093/clinchem/18.6.499 ] [PMID: 4337382]
[28]
Cruz Silva, M.M.; Madeira, V.M.; Almeida, L.M.; Custódio, J.B. Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure. Biochim. Biophys. Acta, 2000, 1464(1), 49-61.
[http://dx.doi.org/10.1016/S0005-2736(99)00237-0 ] [PMID: 10704919]
[29]
Cruz Silva, M.M.; Madeira, V.M.; Almeida, L.M.; Custódio, J.B. Hydroxytamoxifen interaction with human erythrocyte membrane and induction of permeabilization and subsequent hemolysis. Toxicol. In Vitro, 2001, 15(6), 615-622.
[http://dx.doi.org/10.1016/S0887-2333(01)00079-0 ] [PMID: 11698160]
[30]
Yao, J.C.; Thomakos, N.; McLaughlin, P.; Buchholz, T.A.; Kudelka, A.P. Tamoxifen-induced thrombocytopenia. Am. J. Clin. Oncol., 1999, 22(5), 529-532.
[http://dx.doi.org/10.1097/00000421-199910000-00022 ] [PMID: 10521073]
[31]
Behjati, S.; Frank, M.H. The effects of tamoxifen on immunity. Curr. Med. Chem., 2009, 16(24), 3076-3080.
[http://dx.doi.org/10.2174/092986709788803042 ] [PMID: 19689284]
[32]
Love, R.R.; Mamby, C.C.; Feyzi, J.M. Tamoxifen-induced decreases in total cholesterol with 2 weeks of treatment. J. Natl. Cancer Inst., 1993, 85(16), 1344-1345.
[http://dx.doi.org/10.1093/jnci/85.16.1344 ] [PMID: 8340948]
[33]
Hozumi, Y.; Kawano, M.; Hakamata, Y.; Miyata, M.; Jordan, V.C. Tamoxifen inhibits lipoprotein activity: in vivo and in vitro studies. Horm. Res., 2000, 53(1), 36-39.
[PMID: 10965219]
[34]
Cole, L.K.; Jacobs, R.L.; Vance, D.E. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology, 2010, 52(4), 1258-1265.
[http://dx.doi.org/10.1002/hep.23813 ] [PMID: 20658461]
[35]
Lin, C.; Chen, L-S.; Kuo, S-J.; Chen, D-R. Adjuvant tamoxifen influences the lipid profile in breast cancer patients. Breast Care (Basel), 2014, 9(1), 35-39.
[http://dx.doi.org/10.1159/000358752 ] [PMID: 24803885]
[36]
Gudbrandsen, O.A.; Rost, T.H.; Berge, R.K. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J. Lipid Res., 2006, 47(10), 2223-2232.
[http://dx.doi.org/10.1194/jlr.M600148-JLR200 ] [PMID: 16864897]
[37]
Reckless, J.; Metcalfe, J.C.; Grainger, D.J. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation, 1997, 95(6), 1542-1548.
[http://dx.doi.org/10.1161/01.CIR.95.6.1542 ] [PMID: 9118523]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 25
Year: 2020
Published on: 19 August, 2020
Page: [2281 - 2288]
Pages: 8
DOI: 10.2174/1568026620666200819145526
Price: $65

Article Metrics

PDF: 20
HTML: 3